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Summary In order to assess the blood flow patterns through human lung tumours, 20 patients received 400-
750MBq 99TcmHMPAO intravenously 10min before single photon emission computed tomography (SPECT).
Ratios of uptake in the whole tumour relative to normal lung ranged from 0.35 to 1.53 (mean 1.01) with eight
tumours showing less uptake than normal lung and ten showing greater uptake. In one patient the tumour
was not distinguishable from surrounding lung and in another a large pleural effusion prevented evaluation.
Tumour:lung ratios for central tumour regions ranged from 0 to 1.83 (mean 0.80) with 13 showing lower
uptake than normal lung and five showing greater uptake. Duplicate scans were performed in eight patients
demonstrating satisfactory reproducibility. This technique provides a simple and reproducible method for the
assessment of tumour blood flow.
The blood supply of a tumour may be important both in its
natural history, influencing metabolism and growth, and in
determining response to therapy. Since hypoxic cells are
radioresistant and since an inadequate blood supply may
limit drug access, an increase in tumour blood flow might
enhance responsiveness. One method of achieving this is
angiotensin-induced hypertension, which has been evaluated
in both animals and in man (Wakui & Suzuki, 1983) as a
means of improving the response to chemotherapy. Alterna-
tively, vasoactive drugs such as hydralazine reduce blood
flow through animal tumours (Vorhees & Babbs, 1982),
potentiating the cytotoxicity of chemotherapeutic agents such
as melphelan (Stratford et al., 1987) and bioreductive agents
such as RSU-1069 (Chaplin & Acker, 1987). In order to
evaluate such therapeutic possibilities, a simple and re-
producible means of assessing tumour blood flow is essential.
Variations in regional blood flow may be demonstrated by
the use of agents which bind to tissues in proportion to their
blood supply. Such an agent is technetium-99m labelled
hexamethylpropyleneamineoxine (99TcmHMPAO).
99TcmHMPAO was evaluated first in the investigation of
disorders of cerebral blood flow (Podreka et al., 1987) and
later in the study of brain tumours (Babich et al., 1988). In
mice (Hammersley et al., 1987), uptake of 99TcmHMPAO
into tumour and normal tissues correlates closely with the
uptake of rubidium-86. Differences are accounted for by
99TcmHMPAO metabolism in the liver, rubidium excretion
via the kidneys and the relative impermeability of the blood-
brain barrier to rubidium ions. A large difference in normal
lung uptake (greater for 99TcmHMPAO) probably reflects the
lower extraction efficiency of rubidium at high flow rates. In
the same study (Hammersley et al., 1987), uptake of
99TcmHMPAO correlated well with that of rubidium when
changes in blood flow through tumour and normal tissue
(muscle, skin, spleen and gut) were brought about by
Nembutal anaesthesia and by propranolol.
A previous study of blood flow in non-cerebral tumours
using 99TcmHMPAO (Tait et al., 1987) included seven
patients with lung tumours. These patients are the first seven
of the present series, which has been extended to assess the
reproducibility of the technique, to evaluate the relationship
between tumour uptake and tumour size and to investigate
regional blood flow differences within tumours.
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Patients and methods
Twenty patients (17 male, 3 female) were studied between
January 1986 and April 1988 (Table I). The median age was
70.5 years (range 28-81). Eighteen patients had carcinoma of
the bronchus (one adenocarcinoma, one small-cell carcinoma
and the remainder squamous carcinoma) and two had
pulmonary metastases (one from an adenocarcinoma of
unknown origin and the other from an anaplastic thyroid
carcinoma). At the time of scanning only one patient (no.
15) had received radiotherapy to the chest and this had been
seven months previously.
Single photon emission computed tomography (SPECT)
was performed 10min after intravenous injection of 400-
750MBq 99TcmHMPAO (Ceretec, Amersham International).
Patients 1-7 received 750MBq 99TcmHMPAO (Tait et al.,
1987) and the remainder received 400MBq. We obtained 360
degree acquisitions (64 views, 20 seconds per view) using a
General Electric Starcam digital camera system using a low
energy high resolution collimator. Tomographic images of
64 x 64 pixels (with a pixel size of 6mm) were reconstructed
in transaxial, coronal and sagittal planes using a Ramp-
Hanning filter with a cut-off frequency of 0.7cm-1. An
attenuation correction was applied using an attenuation
coefficient of 0.12cm-1 and a threshold value of 4% to
determine the patient outline.
Transaxial, coronal and sagittal sections were reviewed to
determine those that intersected through the centre of the
tumour mass. On the selected transaxial view tracer uptake
within the tumour was determined by the superimposition of
two regions of interest (ROI) (Figure 3c). The first ROI was
of sufficient size to encompass the whole tumour with a
minimum amount of adjacent lung while a 3 x 3 pixel ROI
was used to define the central part of the tumour in which
maximum or minimum values of tracer uptake could be
identified. A third ROI of identical shape and size to the
first was placed over an area of normal contralateral lung in
the same coronal plane. This position was chosen in order to
minimise any regional variations in pulmonary blood flow.
In two instances where this was not possible (both were in
right middle lobe tumours where the heart lies within the
desired region of 'normal lung' (as in Figure 4a), smaller
regions of interest were used (as in Figure 4d).
For each ROI, the mean number of counts per pixel (and
standard error) was recorded. In one case where the mean
pixel count was negative as a result of reconstruction
(patient 12), this value was set to zero. From these values
tumour:lung ratios were calculated for both the whole
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Table I Patient characteristics
Patient
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Primary
Age tumour
74
28
81
74
69
46
59
74
78
71
75
70
68
63
74
70
78
67
79
66
Bronchus
Unknown
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Thyroid
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
Bronchus
tumour and the tumour centre. Profiles of uptake across
single transaxial sections were obtained through the tumour
centre in sagittal and coronal planes .and displayed graphi-
cally (Figure 4b-d). In eight patients the whole procedure
was repeated 3-5 days later to assess reproducibility. Initial
and repeat scans were evaluated with ROTs of identical size.
Plain chest radiographs were used to assess tumour size.
Two perpendicular diameters (X, Y) were measured directly
from the PA view without demagnification. Where lateral
views were not available the third tumour dimension (Z) was
calculated as the mean of the other two. Seven tumours were
not assessable in this way; mostly this was because of
adjacent areas of collapse or consolidation. Tumour volume
was calculated as:
47r (Xx Yx Z)
volume= 3
8
The strength of the relationship between central tumour
uptake ratio and tumour size was assessed by linear regres-
sion analysis.
Histology
Adenocarcinoma poorly diff.
Adenocarcinoma
Squamous carcinoma
Squamous carcinoma
Squamous carcinoma
Small-cell carcinoma
Squamous carcinoma mod. diff.
Squamous carcinoma poorly diff.
Squamous carcinoma
Squamous carcinoma
Squamous carcinoma poorly diff.
Anaplastic carcinoma
Squamous carcinoma mod. diff.
Squamous carcinoma poorly diff.
Squamous carcinoma
Squamous carcinoma mod. diff.
Squamous carcinoma
Squamous carcinoma poorly diff.
Squamous carcinoma
Squamous carcinoma poorly diff.
Lung
site
RLL
RUL
LUL
LLL
RML
RML
RUL
Post. LLL
RML/RUL
RLL/RML
RUL
Post. RUL
RUL
RLL
LUL
Apex RLL
Apex LLL
Lat. RML
Apex RLL
Post. RLL
Table II Tumour volumes and tumour:lung ratios
Tumour
Patient volume
no. (mi)
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
336
U
95
U
U
U
75
33
U
U
184
509
116
98
168
U
144
33
78
718
Initial Scan Repeat Scan
w C W C
0.97
1.18
1.20
a
0.89
0.50
b
0.62
1.19
1.42
0.67
0.50
1.23
1.27
0.91
1.03
1.36
1.53
1.29
0.35
0.38
0.86
0.69
a
0.37
0.24
b
0.58
1.75
1.82
0.31
0.000C
1.40
0.97
0.17
0.81
1.83
1.38
0.88
0.003
0.57
1.41
1.46
0.65
0.45
1.18
1.30
0.96
0.53
1.94
1.83
0.25
0.004
1.28
0.96
0.05
Results
Table II shows the tumour:lung uptake ratios for the 20
tumours. These ranged from 0.35 to 1.53 (mean 1.01) for the
whole tumour with eight tumours showing lower uptake and
ten showing higher uptake than normal contralateral lung
(Figure 1). Central tumour uptake ratios ranged from 0 to
1.83 (mean 0.80) with 13 tumours exhibiting lower and five
exhibiting higher uptake than normal lung. In all but four
instances uptake ratios were lower in central regions than in
the tumour as a whole. In one patient (no. 7) the tumour
was not distinguishable from surrounding lung and in
another (no. 4) a large pleural effusion prevented further
evaluation.
Figure 2a-d (patient 12) and Figure 3a-d (patient 9) show
an example each of reduced and increased tumour uptake. In
patient 12, conventional X-ray tomography confirmed the
solid nature of the lesion.
Considerable inhomogeneity of uptake was seen. Figure 4a
(patient 18) shows the tumour periphery as a ring of higher
uptake surrounding a central area of lower uptake, although
in this instance the centre still shows greater uptake than
normal lung. This 'ring' appearance was seen in all three
planes of reconstruction. In other instances, the ring did not
always encircle the whole tumour nor was it of uniform
W, whole tumour:lung ratio; C, central tumour:lung
ratio; aLarge pleural effusion; bTumour indistinguishable
from surrounding lung; U, tumour volume unassessable;
cSee text.
thickness or intensity. The use of profile curves in Figure 4
further illustrates this pattern of blood flow distribution. Of
the 13 patients with reduced central uptake, only one
(patient 11) had evidence of cavitation on plain chest
radiograph.
There were no significant differences in tumour:lung
uptake ratio by histological type.
Figure 5 shows the relationship between tumour volume
and central tumour uptake ratio in the 13 patients with
measurable tumours. Log of tumour size versus log of
central uptake was analysed because of evidence that obser-
vations of tracer uptake are better described by a power
relationship (Williams et al., 1988). For this analysis, the
tumour:lung ratio of patient 7 (where uptake within a 5cm
tumour could not be distinguished from that in surrounding
lung) was taken to be 1.0. Where two scans had been
performed, the mean of the two ratios was used. Log of
tumour volume and log of central uptake ratio were seen to
be inversely related (r= -0.78; P=0.002). There was a less
strong relationship between whole tumour uptake ratio andTECHNETIUM-99mHMPAO AND SPECT 137
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Figure 1 Tumour: lung uptake ratios.
size (r -0.61; P<0.05). Central tumour uptake was de-
scribed by the equation:
uptake ratio = 2952 x (tumour volume)-
Table II also shows tumour: lung ratios seen in eight
patients who underwent repeat scanning. Values for repeat
tumour:lung ratios lay within the range 90.9-118.4% of the
initial scan values for whole tumour (mean 100.4%) and
26.4-111.0% for the tumour centre (patient 12 could not be
analysed in this way as the initial central tumour uptake was
zero). The two sets of ratios (with standard errors) are
displayed graphically in Figure 6a and b. Repeat uptake
ratios are closely correlated both for whole tumour (r = 0.98;
P<0.001) and for the tumour centre (r=0.99; P<0.001).
Discussion
Technetium-99m labelled HMPAO with SPECT is an effec-
tive technique for demonstrating lung tumours and regional
variations in blood flow. Although planar views alone will
detect tumours that are large or have a well-vascularised
periphery, tomography is necessary for the visualisation of
regional differences.
A strong correlation between paucity of uptake within
tumour centres and increasing tumour size was seen in this
series. This is consistent with reported changes in tumour
blood flow with increasing size in experimental animal
tumours (Gullino & Grantham, 1961; Vaupel, 1975). How-
ever, phantom studies show that analysis of the relationship
between tumour size and actual 99TcmHMPAO uptake is
complicated by an additional (though smaller) dependence of
measured activity on tumour site and size, (Inamdar, 1982;
Webb et al., 1986; Clarke et al., 1986; N.P. Rowell, unpub-
lished data). This causes peripheral lesions to appear 'hotter'
than central lesions containing the same activity. For smaller
lesions containing less activity than background there is an
overestimate of the true activity because of a relatively
greater contribution from scattered photons from the sur-
rounding medium to the centres of smaller sources. Conver-
sely, when smaller sources contain higher activity than
background an underestimate will result. From these studies
(N.P. Rowell, unpublished data), it is possible to correct for
size to determine the actual activity in the tumour relative to
surrounding normal lung. When this is done, there is in fact
little change in the overall relationship between uptake ratio
and tumour volume (slope= -1.83, r= -0.75, P<0.01).
When considering uptake ratios for the whole tumour,
satisfactory reproducibility is seen for the series as a whole,
though individual values differed by up to 18.4%. Factors
contributing to this include differences in patient and camera
positioning between scans, intra-observer variation in the
interpretation of images and possible day-to-day variation in
tumour blood flow. Reproducibility was less satisfactory for
individual central tumour: lung ratios than for the group as
a whole, the most discordant values being seen where central
uptake was lowest. This may represent sampling error (in
spite of careful search for lowest values) or a genuine
variability in central tumour blood flow.
An absolute measure of tumour blood flow would be ideal
but this is complicated by a variety of physical factors.
Furthermore, since primary lung tumours appear to derive
their blood supply almost entirely from the systemic circula-
tion (Milne, 1967), absolute tumour uptake would be
expected to be in proportion to cardiac output, which would
then need to be measured on each occasion.
Other radiopharmaceuticals are less satisfactory in the
assessment of tumour blood flow. Mostly this is because
their binding to tissues is not related simply to blood flow.
With the exception of radioactive microspheres (which need
to be given directly into the left ventricle or the aorta and
are therefore rarely justified in the clinical situation), studies
with intravenous rubidium chloride are generally considered
to give the best indication of tumour blood flow (Gullino &
Grantham, 1961). While correlating well with uptake of
rubidium-86 (Hammersley et al., 1987), cellular uptake of
99TcmHMPAO is not an active process. As a result,
99TcmHMPAO may bind to cells which are no longer viable
(and which no longer take up rubidium) provided perfusion
remains unimpaired (P. Hammersley, personal communica-
tion). This may be seen as an advantage for 99TcmHMPAO
in that interpretation of blood flow images following, for
example, vasoactive agents does not require consideration of
cellular viability.
Thallium rather than rubidium has been used in several
studies of human tumours. Thallium and rubidium, being
potassium analogues, enter cells by similar pathways (Sessler
et al., 1986) and give similar indications of blood flow
(Leppo, 1987). The disadvantages of thallium-201 derive
from the lower energy of emitted photons, which contributes
to poor spatial resolution.
While uptake of potassium analogues reflects blood flow,
uptake of gallium and 99Tcm-glucoheptonate clearly depends
on additional factors. In studies of patients with carcinoma
of the bronchus but not using SPECT, uptake ratios of
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Figure 2 Uptake of 99TcmHMPAO in patient 12: (a) transaxial SPECT image through tumour centre; (b) sagittal SPECT image
through tumour centre; (c) coronal SPECT image through tumour centre; (d) PA chest X-ray.TECHNETIUM-99mHMPAO AND SPECT 139
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Figue 3 Uptake of 99TcmHMPAO in patient 9: (a) transaxial SPECT image through tumour centre; (b) sagittal SPECT image
through tumour centre; (c) as (a) with positions of regions of interest; (d) PA chest X-ray.N.P. ROWELL et al.
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Figure 4 Uptake of 99TcmHMPAO in patient 18: (a) transaxial SPECT image through tumour centre; (b) sagittal profile curve;
(c) coronal profile curve; (d) as (a) with positions of profile curves and regions of interest. T, tumour; H, heart.
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Figure 5 Central tumour:lung uptake ratio versus tumour
volume.
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Figure 6 (a) Whole tumour:lung uptake ratios for initial and
repeat scans in eight patients; (b) Central tumour:lung uptake
ratios for initial and repeat scans in eight patients.
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thallium-201:gallium-67 varied with histology (Togawa et al.,
1985) and with doubling time (Togawa et al., 1986), faster
growing tumours showing greater uptake of both agents but
a lower ratio. In a similar series also without SPECT (Vorne
et al., 1987), there were no significant differences in uptake
of 99Tcm!-glucoheptonate and gallium-67 citrate between histo-
logical types.
In conclusion, 99TcmHMPAO with SPECT is an effective
and reproducible technique for demonstrating patterns of
blood flow in thoracic tumours. It offers considerable poten-
tial for the evaluation of treatment strategies which either
produce or rely upon changes in tumour perfusion.
We are grateful to Amersham International for the supply of
Ceretec, to Dr N.T. Cooke, Dr P. Jones and Dr J.R. Yarnold for
permission to report on patients under their care, and to Dr N.
Rawson for statistical advice.
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